MicroRNA对药物转运体调控作用的研究进展

中国临床药理学与治疗学 ›› 2014, Vol. 19 ›› Issue (9): 1064-1068.

MicroRNA对药物转运体调控作用的研究进展

刘莉^{1, 2}, 郭成贤², 彭金富^{1, 2}, 黄洁², 阳国平²

¹ 中南大学药学院,长沙 410013,湖南;
² 中南大学湘雅三医院,长沙 410013,湖南

收稿日期:2013-11-25 修回日期:2014-07-11 出版日期:2014-09-26 发布日期:2014-09-26
通讯作者: 阳国平,男,教授,硕士生导师,主要从事临床药理学与药代动力学研究。 Tel: 0731-88618339 E-mail: ygp9880@163.com
作者简介:刘莉,女,硕士研究生,主要从事药代动力学研究。 Tel: 13469079764 E-mail: liuli2013good@163.com
基金资助:
国家自然科学基金(81373476); 中南大学自主探索创新基金(2014zzts314); 国家重大新药创制科技重大专项基金资助项目(2012ZX0903014-001)

Development of microRNA-dependment control of drug transporter

LIU Li^{1, 2}, GUO Chen-xian², PENG Jin-fu^{1, 2}, HUANG Jie², YANG Guo-ping²

¹ College of Pharmacy, Central South University, Changsha 410013, Hunan, China;
² the Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China

Received:2013-11-25 Revised:2014-07-11 Online:2014-09-26 Published:2014-09-26

摘要/Abstract

摘要： MicroRNA作为一类单链非编码小分子RNA,通过与靶基因mRNA 3'端非编码区(3'-untranslated region,3'-UTR)的互补结合来调节靶基因的表达,在生物发育、细胞分化、增殖和凋亡中发挥重要作用,与人类多种疾病如恶性肿瘤、糖尿病等的发生发展密切相关。MicroRNA表达的变化可影响药物代谢酶和转运体的表达,进而影响药物效应。目前有关药物代谢酶的研究较为深入,而对转运体的研究则相对较少。本文通过总结近几年国内外相关研究,从MicroRNA的作用机制及其对药物转运体的调控作用方面进行综述,以期为指导临床个体化用药提供理论依据。

关键词: MicroRNA, 转运体, 调控作用

Abstract: MicroRNA is a class of small non-coding single-stranded molecule RNA, regulating the expression of target genes though complementary binding with the target gene mRNA 3 'untranslated region (3'-untranslated region, 3'-UTR) and plays an important role in biology developmental, cell differentiation, proliferation and apoptosis. And it closely related to the occurrence and development with many human diseases such as cancer, diabetes and so on. Drug-metabolizing enzymes and transporters expression can be affected by the changes of MicroRNA expression, thereby affecting drug effect. Current researches on drug metabolizing enzymes are more in-depth, while the transporters are relatively small. This paper summarizes research at home and abroad in recent years, the mechanism of action about MicroRNA and its regulation about drug transporter were reviewed. So as to provide a theoretical basis to guide the clinical individualized medicine.

Key words: MicroRNA, transporters, regulation

中图分类号:

R969.1

刘莉, 郭成贤, 彭金富, 黄洁, 阳国平. MicroRNA对药物转运体调控作用的研究进展[J]. 中国临床药理学与治疗学, 2014, 19(9): 1064-1068.

LIU Li, GUO Chen-xian, PENG Jin-fu, HUANG Jie, YANG Guo-ping. Development of microRNA-dependment control of drug transporter[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 1064-1068.

参考文献 38

[1]	周宏灏,主编.遗传药理学[M]. 北京科学出版社, 2001.
[2]	Glubb DM, Innocenti F.Mechanisms of genetic regulation in gene expression: examples from drug metabolizing enzymes and transporters[J]. Wiley Interdiscip Rev Syst Biol Med., 2011, 3(3): 299-313.
[3]	郭瑜, 周宏灏, 刘昭前. miRNA 与药物反应个体差异[J]. 中国临床药理学与治疗学, 2013, 18(4): 443-448.
[4]	Bartel DP.MicroRNAs: target recognition and regulatory functions[J]. Cell, 2009, 136(2): 215-233.
[5]	Toscano-Garibay JD, Aquino-Jarquin G.Regulation exerted by miRNAs in the promoter and UTR sequences: MDR1/P-gp expression as a particular case[J]. DNA Cell Biol, 2012, 31(8): 1358-1364.
[6]	Shukla GC, Singh J, Barik S.MicroRNAs: processing, maturation, target recognition and regulatory functions[J]. Mol Cell Pharmacol, 2011, 3(3): 83.
[7]	Lim LP, Lau NC, Garrett-Engele P, et al.Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs[J]. Nature, 2005, 433: 769-773.
[8]	Ho RH, Kim RB.Transporters and drug therapy: implications for drug disposition and disease[J]. Clin Pharmacol Ther, 2005, 78(3): 260-277.
[9]	马丁. 卵巢癌多药耐药机制的探讨[J]. 中华妇幼临床医学杂志, 2007, 8(3): 184-188.
[10]	Zhu H, Wu H, Liu X, et al.Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells[J]. Biochem Pharmacol, 2008, 76(5): 582-588.
[11]	Li Z, Hu S, Wang J, et al.MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells[J]. Gynecol Oncol, 2010, 119(1): 125-130.
[12]	Chen Z, Ma T, Huang C, et al.MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells[J]. Cell Signal, 2013, 25(12):2693-701.
[13]	Yang T, Zheng Z, Li X, et al.MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells[J]. Exp Biol Med (Maywood), 2013, 238(9): 1024-1032.
[14]	Xu Y, Xia F, Ma L, et al.MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest[J]. Cancer Lett, 2011, 310(2): 160-169.
[15]	Xia L, Zhang D, Du R, et al.miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells[J]. Int J Cancer, 2008, 123(2): 372-379.
[16]	Bao L, Hazari S, Mehra S, et al.Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298[J]. Am J Pathol, 2012, 180(6): 2490-2503.
[17]	Wang F, Li T, Zhang B, et al.MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN[J]. Biochem Biophys Res Commun, 2013, 434(3):688-94.
[18]	Yang L, Li N, Wang H, et al.Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance[J]. Oncol Rep, 2012, 28(2): 592-600.
[19]	Kovalchuk O, Filkowski J, Meservy J, et al.Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin[J]. Mol Cancer Ther, 2008, 7(7): 2152-2159.
[20]	Chen J, Tian W, Cai H, et al.Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer[J]. Med Oncol, 2012, 29(4): 2527-2534.
[21]	Ikemura K, Yamamoto M, Miyazaki S, et al.MicroRNA-145 post-transcriptionally regulates the expression and function of P-glycoprotein in intestinal epithelial cells[J]. Mol Pharmacol, 2013, 83(2): 399-405.
[22]	Haenisch S, Laechelt S, Bruckmueller H, et al.Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379[J]. Mol Pharmacol, 2011, 80(2): 314-320.
[23]	Borel F, Han R, Visser A, et al.Adenosine triphosphate-binding cassette transporter genes up‐regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs[J]. Hepatology, 2012, 55(3): 821-832.
[24]	Padmanabhan R, Chen KG, Gillet JP, et al.Regulation and expression of the ATP-binding cassette transporter ABCG2 in human embryonic stem cells[J]. Stem Cells, 2012, 30(10): 2175-2187.
[25]	Ma MT, He M, Wang Y, et al.MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2)[J]. Cancer Lett, 2013, 339(1): 107-115.
[26]	Jiao X, Zhao L, Ma M, et al.MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2)[J]. Breast Cancer Res Treat, 2013, 139(3): 717-30.
[27]	Pan YZ, Morris ME, Yu AM.MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells[J]. Mol Pharmaco, 2009, 75(6): 1374-1379.
[28]	Turrini E, Haenisch S, Laechelt S, et al.MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression[J]. Pharmacogenet Genomics, 2012, 22(3): 198-205.
[29]	Li WQ, Li YM, Tao BB, et al. Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance[J]. Med Sci Monit, 2010, 16(10): HY27.
[30]	Li X, Pan YZ, Seigel GM, et al.Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells[J]. Biochem Pharmacol, 2011, 81(6): 783-792.
[31]	Shen WW, Zeng Z, Zhu WX, et al.MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells[J]. J Mol Med (Berl), 2013, 91(8):989-1000.
[32]	Wang F, Xue X, Wei J, et al.Hsa-miR-520h down-regulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations[J]. Br J Cancer, 2010, 103(4): 567-574.
[33]	Zaïr ZM, Eloranta JJ, Stieger B, et al.Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney[J]. Pharmacogenomics, 2008, 9(5): 597-624.
[34]	Fisher CD, Lickteig AJ, Augustine LM, et al.Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats[J]. Eur J Pharmacol, 2009, 613(1): 119-127.
[35]	Pogribny IP, Starlard-Davenport A, Tryndyak VP, et al.Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice[J]. Lab Invest, 2010, 90(10): 1437-1446.
[36]	Cheung O, Puri P, Eicken C, et al.Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression[J]. Hepatology, 2008, 48(6): 1810-1820.
[37]	Cermelli S, Ruggieri A, Marrero JA, et al.Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease[J]. PLoS One, 2011, 6(8): e23937.
[38]	Brown BD, Naldini L.Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications[J]. Nat Rev Genet, 2009, 10(8): 578-585.